Fused azepinone cyclin dependent kinase inhibitors

US6610684B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Department of Health and Human Services · US
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR

Inventors

• Daniel W. Zaharevitz · Camp Springs, US
• Rick Gussio · Frederick, US
• Ravi Kumar Jalluri · San Diego, US
• Edward A. Sausville · Silver Spring, US
• Conrad Kunick · Hamburg, DE
• Laurent Meijer · Morlaix, FR

Key dates

• Filing date: Dec 14, 2000
• Grant date: Aug 26, 2003
• Expiry date: Dec 14, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

A new class of cyclin dependent kinase inhibitors that also have antiproliferative activity in human tumor cell line assays are described. Most of these compounds satisfy the formula wherein A is oxygen or sulfur coupled to the right by a single or double bond; R2 is selected from the group consisting of hydrogen, aryl, lower aliphatic substituents, particularly alkyl and lower alkyl ester; R4-R7 are independently selected from the group consisting of alkoxy, amino, acyl, aliphatic substituents, particularly alkyl, alkenyl and alkinyl substituents, aliphatic alcohols, particularly alkyl alcohols, aliphatic nitriles, particularly alkyl nitriles, cyano, nitro, carboxyl, halogen, hydrogen, hydroxyl, imino, and &agr;, &bgr;, unsaturated ketones; R8-R11 are independently selected from the group consisting of aliphatic substituents, particularly alkyl, alkenyl and alkinyl substituents, particularly lower aliphatic substituents, alipahatic alcohols, particularly alkyl alcohols, alkoxy, acyl, cyano, nitro, epoxy, haloalkyl groups, halogen, hydrogen and hydroxyl; R12 is selected from the group consisting of aliphatic groups, particularly lower alkyl groups, aliphatic alcohols, particularly …